TG Therapeutics to show phase 4 and paediatric trial updates for Briumvi at ACTRIMS 2026
TG Therapeutics, Inc. announced the upcoming schedule of presentations highlighting Briumvi (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum,… read more.
